Improved patient outcomes can be only achieved in an interdisciplinary approach, through the synergistic combination of an efficient disruption of lymphoma cell-intrinsic oncogenic programs and a specific modulation of the lymphoma (immune) microenvironment.

The backbone of the SFB1530 is a unique network of internationally visible basic and translational researchers working on key aspects of lymphoma and inflammation biology with clinical lymphoma researchers at the partner sites Berlin, Cologne, Essen, Frankfurt and Heidelberg.